Actinium Pharmaceuticals, Inc. (ATNM)

1.780.01 (-0.56%)

Actinium Pharmaceuticals, Inc. (ATNM) stock comprehensive Revenue breakdown by product and country/region. Analyze revenue sources and geographic exposure.

High Bankruptcy RiskBelow Average ESGFair ValuationLow ProfitabilityAdequate Financial HealthInefficient OperationsModerate GrowthLow QualityAdequate Dividend ProfileIndustry Rank: 20.71%Sector Rank: 20.27%

AMEX - Healthcare - Biotechnology | Market Cap: 55.53M | Next Earnings Date: 13 Nov 2025

Day's Range

1.75 - 1.81

52-Week Range

1.03 - 2.41

Volume

122.5K / 297.6K (Avg.)

P/E Ratio | EPS

-1.36 | -1.31

Trending:

ATNM stock Revenue Breakdown by Products

View the company's revenue segmentation by reporting period and analyze the trends over time.

Select Reporting Period

Sep 30, 2023 Jan 01, 2000

License

$35.00M

No previous data to compare.

Select Segment for Chart